US 12,030,940 B2
Immunotherapeutic tumor treatment method
Jonathan Zalevsky, Berkeley, CA (US); Neel K. Anand, San Mateo, CA (US); Haiying Cai, Cupertino, CA (US); Bo-Liang Deng, San Ramon, CA (US); Zhongxu Ren, Foster City, CA (US); Bhalchandra V. Joshi, Madison, AL (US); Mary Tagliaferri, San Anselmo, CA (US); Werner Rubas, Redwood City, CA (US); Saul Kivimae, San Francisco, CA (US); and Rhoneil L. Pena, Fremont, CA (US)
Assigned to Nektar Therapeutics, San Francisco, CA (US)
Appl. No. 16/639,520
Filed by Nektar Therapeutics, San Francisco, CA (US)
PCT Filed Aug. 17, 2018, PCT No. PCT/US2018/000318
§ 371(c)(1), (2) Date Feb. 14, 2020,
PCT Pub. No. WO2019/036031, PCT Pub. Date Feb. 21, 2019.
Claims priority of provisional application 62/546,896, filed on Aug. 17, 2017.
Prior Publication US 2021/0130467 A1, May 6, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 14/55 (2006.01)
CPC C07K 16/2818 (2013.01) [C07K 14/55 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A kit comprising:
(a) a PD-1/PD-L1 axis inhibitor;
(b) a toll-like receptor (TLR) agonist covalently attached to a multi-arm, water-soluble, non-peptidic polymer, wherein the TLR agonist is selected from a multi-armed polymer conjugate of R848, a multi-armed polymer conjugate of imiquimod, or a multi-armed polymer conjugate of 44(6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)-benzamide; and
(c) an IL-2Rβ-activating amount of a long acting interleukin-2 receptor beta (IL-2Rβ)-preferential agonist; and
instructions for their administration to a subject having a cancer.